标题
Toll-Like Receptor-Based Strategies for Cancer Immunotherapy
作者
关键词
-
出版物
Journal of Immunology Research
Volume 2021, Issue -, Pages 1-14
出版商
Hindawi Limited
发表日期
2021-05-25
DOI
10.1155/2021/9912188
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects
- (2020) Gary J. Haderski et al. PLoS One
- IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer
- (2020) Margaux Hubert et al. Science Immunology
- Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
- (2020) Lukas Amon et al. Pharmaceutics
- Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
- (2020) Xiaomei Wang et al. Blood Advances
- Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists
- (2020) Stefano Federico et al. JOURNAL OF MEDICINAL CHEMISTRY
- Macrophage-based approaches for cancer immunotherapy
- (2020) Nicholas R. Anderson et al. CANCER RESEARCH
- Toll‐like receptor‐2/7‐mediated T cell activation: An innate potential to augment CD8 + T cell cytokine production
- (2020) Julian J. Freen‐van Heeren SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities
- (2020) Ashleigh S. Davey et al. Cancers
- A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine
- (2019) Hyun Jin Park et al. Journal for ImmunoTherapy of Cancer
- Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
- (2019) Matthew R. Collinson-Pautz et al. LEUKEMIA
- Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells
- (2019) Duaa Babaer et al. Cancers
- Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells
- (2019) Shengmeng Di et al. Frontiers in Oncology
- A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy
- (2019) Tsukasa Seya et al. ADVANCED DRUG DELIVERY REVIEWS
- TLR9 agonist adsorbed to alum adjuvant prevents asthma‐like responses induced by Blomia tropicalis mite extract
- (2019) Fernanda P. B. Nunes et al. JOURNAL OF LEUKOCYTE BIOLOGY
- A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients
- (2019) Marit M. Melssen et al. Journal for ImmunoTherapy of Cancer
- The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study
- (2019) Rebecca Ronsley et al. PEDIATRIC HEMATOLOGY AND ONCOLOGY
- Toll-Like Receptor 7 Activation Enhances CD8+ T Cell Effector Functions by Promoting Cellular Glycolysis
- (2019) Qian Li et al. Frontiers in Immunology
- Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential
- (2019) Mohammad-Hossein Haddadi et al. BLOOD REVIEWS
- Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma
- (2019) Anna Pavlick et al. Cancer Immunology Research
- TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
- (2019) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages
- (2019) Zhipeng Liu et al. CANCER LETTERS
- Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy
- (2019) Qin Zeng et al. CURRENT OPINION IN BIOTECHNOLOGY
- Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models
- (2018) Yohei Takeda et al. CANCER SCIENCE
- TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy
- (2018) Lan Huang et al. Cellular & Molecular Immunology
- CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity
- (2018) Jing Jie et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-αβ Signaling and Restricts Tumor Progression
- (2018) Aurobind Vidyarthi et al. Frontiers in Immunology
- The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
- (2018) Rhea N. Coler et al. npj Vaccines
- Recent clinical trends in Toll-like receptor targeting therapeutics
- (2018) Muhammad Ayaz Anwar et al. MEDICINAL RESEARCH REVIEWS
- Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation
- (2018) Elisabeth Müller et al. Frontiers in Immunology
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy
- (2018) Melody Smith et al. OncoImmunology
- Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
- (2017) Shikhar Mehrotra et al. Journal of Hematology & Oncology
- Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells
- (2017) Y Lai et al. LEUKEMIA
- Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40
- (2017) Aaron E. Foster et al. MOLECULAR THERAPY
- Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy
- (2017) V Mett et al. ONCOGENE
- NK cell-based immunotherapy for cancer
- (2017) Fang Fang et al. SEMINARS IN IMMUNOLOGY
- Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy
- (2017) Misako Matsumoto et al. Frontiers in Immunology
- Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases
- (2017) Lupe G. Salazar et al. JAMA Oncology
- A Randomized Trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer
- (2016) C.P. Belani et al. ANNALS OF ONCOLOGY
- Abstract 4885: Intratumoral injection of G100 (TLR4 agonist glycopyranosyl lipid A) modulates tumor microenvironment and induces CD8 T cell-dependent, systemic anti-tumor immunity
- (2016) Hailing Lu et al. CANCER RESEARCH
- Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
- (2016) Laura Q.M. Chow et al. CLINICAL CANCER RESEARCH
- Recent progress in the development of Toll-like receptor (TLR) antagonists
- (2016) Mahesh Chandra Patra et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Immunological evaluation of colonic delivered Hepatitis B surface antigen loaded TLR-4 agonist modified solid fat nanoparticles
- (2016) Kantrol Kumar Sahu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells
- (2016) Shu Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trial Watch: Immunotherapy plus radiation therapy for oncological indications
- (2016) Erika Vacchelli et al. OncoImmunology
- A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites
- (2015) Craig L. Slingluff et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker
- (2015) Christina Müller et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside
- (2015) Burghardt Wittig et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials
- (2015) Mari S. Oba et al. Gastric Cancer
- Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: A review
- (2015) C.J. de Witte et al. GYNECOLOGIC ONCOLOGY
- Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs
- (2015) Rachid Ammi et al. PHARMACOLOGY & THERAPEUTICS
- Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors
- (2015) Steven A. Feldman et al. SEMINARS IN ONCOLOGY
- TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells
- (2015) Martin Lelaidier et al. Oncotarget
- Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
- (2014) David A. Smith et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence
- (2014) J. Ye et al. EMBO Molecular Medicine
- TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells
- (2014) Francesca Bellora et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Toll-like receptor agonists: a patent review (2011 – 2013)
- (2014) Waleed M Hussein et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Toll-like receptors and B cells: functions and mechanisms
- (2014) Claire M. Buchta et al. IMMUNOLOGIC RESEARCH
- Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
- (2014) Hans-Joachim Schmoll et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Clinical use of dendritic cells for cancer therapy
- (2014) Sébastien Anguille et al. LANCET ONCOLOGY
- Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
- (2014) Julia Scheiermann et al. VACCINE
- Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction
- (2014) A Nicole Desch et al. Nature Communications
- Direct Type I IFN but Not MDA5/TLR3 Activation of Dendritic Cells Is Required for Maturation and Metabolic Shift to Glycolysis after Poly IC Stimulation
- (2014) Austin Pantel et al. PLOS BIOLOGY
- TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells
- (2013) Hongliang Fang et al. Cellular & Molecular Immunology
- Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
- (2013) A. Marabelle et al. CLINICAL CANCER RESEARCH
- Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody
- (2013) M Reilly et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
- (2013) Jean-Pascal Machiels et al. INVESTIGATIONAL NEW DRUGS
- Macrophages Are More Potent Immune Suppressors Ex Vivo Than Immature Myeloid-Derived Suppressor Cells Induced by Metastatic Murine Mammary Carcinomas
- (2013) M. J. Hamilton et al. JOURNAL OF IMMUNOLOGY
- In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC
- (2013) Maryam Nourizadeh et al. Targeted Oncology
- Toll-Like Receptor Signaling
- (2013) K.-H. Lim et al. Cold Spring Harbor Perspectives in Biology
- Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation
- (2013) Y. Yin et al. Cancer Immunology Research
- Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense
- (2012) Shaherin Basith et al. ARCHIVES OF PHARMACAL RESEARCH
- Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers
- (2012) Zhen Huang et al. BIOMATERIALS
- Critical role of Toll-like receptor signaling in NK cell activation
- (2012) Qie Guo et al. CHINESE SCIENCE BULLETIN
- Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells
- (2012) Barbara Drobits et al. JOURNAL OF CLINICAL INVESTIGATION
- Macrophage plasticity and polarization: in vivo veritas
- (2012) Antonio Sica et al. JOURNAL OF CLINICAL INVESTIGATION
- Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A
- (2012) Stacie L. Lambert et al. PLoS One
- CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-κB activation and NO production
- (2012) Xiaoli Li et al. TUMOR BIOLOGY
- A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
- (2011) C. Manegold et al. ANNALS OF ONCOLOGY
- Activation of Toll-like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth
- (2011) Z. Cai et al. CANCER RESEARCH
- TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis
- (2011) Friedrich Horak EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The Toll-Like Receptor 4 Agonist Monophosphoryl Lipid A Augments Innate Host Resistance to Systemic Bacterial Infection
- (2011) Christopher D. Romero et al. INFECTION AND IMMUNITY
- Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Vera Hirsh et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
- (2011) Clive S. Zent et al. LEUKEMIA & LYMPHOMA
- When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function
- (2010) D. Geng et al. BLOOD
- Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
- (2010) Gerty Schreibelt et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis
- (2010) Manabu Taura et al. CANCER SCIENCE
- The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice
- (2010) Fang Ma et al. Cellular & Molecular Immunology
- Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist
- (2010) Thanh Nhan Nguyen Pham et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- TLR1/2, TLR7, and TLR9 Signals Directly Activate Human Peripheral Blood Naive and Memory B Cell Subsets to Produce Cytokines, Chemokines, and Hematopoietic Growth Factors
- (2010) Sudhanshu Agrawal et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Differential but Direct Abolishment of Human Regulatory T Cell Suppressive Capacity by Various TLR2 Ligands
- (2010) H. H. Oberg et al. JOURNAL OF IMMUNOLOGY
- TLR-based immune adjuvants
- (2010) Folkert Steinhagen et al. VACCINE
- Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection
- (2009) Richard T Lester et al. AIDS
- Toll-like Receptors 3 and 7 Agonists Enhance Tumor Cell Lysis by Human T Cells
- (2009) H. Shojaei et al. CANCER RESEARCH
- The contribution of direct TLR signaling to T cell responses
- (2009) Adeeb H. Rahman et al. IMMUNOLOGIC RESEARCH
- AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
- (2009) A. M. Didierlaurent et al. JOURNAL OF IMMUNOLOGY
- Toll-like Receptor 4 Signaling Promotes Tumor Growth
- (2009) Che-Hsin Lee et al. JOURNAL OF IMMUNOTHERAPY
- T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy
- (2008) R. Houot et al. BLOOD
- Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors
- (2008) Masashi Murata CANCER SCIENCE
- Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC- -dependent mechanism
- (2008) A. Paone et al. CARCINOGENESIS
- Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity
- (2008) Nicole Asprodites et al. FASEB JOURNAL
- Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
- (2008) A M Krieg ONCOGENE
- The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice
- (2008) Mohamed L. Salem et al. VACCINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started